

(51) International Patent Classification:
Not classified(21) International Application Number:
PCT/CN2024/087465(22) International Filing Date:
12 April 2024 (12.04.2024)

(25) Filing Language: English

(26) Publication Language: English









(30) Priority Data:
PCT/CN2023/088051
13 April 2023 (13.04.2023) CN(71) Applicant: **BEIGENE SWITZERLAND GMBH**
[CH/CH]; Aeschengraben 27, 4051 Basel (CH).

(72) Inventor; and

(71) Applicant (for SC only): **TSAI, Charng-Sheng** [CN/CN]; No. 30 Science Park Road, Zhongguancun Life Science Park, Changping District, Beijing 102206 (CN).(72) Inventors: **TSAI, Mei-Hsuan**; No. 51 Rijing Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN). **HE, Maomao**; No. 51 Rijing Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN). **WANG, Zewei**; No. 51 Rijing Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN). **YANG, Xiaokun**; No. 51 Rijing Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN). **LI, Lingyan**; No. 51 Rijing Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN).(74) Agent: **WU, FENG & ZHANG**; 3FL, Building 4, Yard 38, LinFengErLu Road, Greenland Central Square, Haidian District, Beijing 100089 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

(54) Title: TARGETED PYRROLOBENZODIAZAPINE CONJUGATES



(57) Abstract: Provided are compounds comprising pyrrolobenzodiazepine (PBD) conjugates and methods of using such conjugates. In some embodiments, a conjugate is of Formula (I), or a pharmaceutically acceptable salt, tautomer, solvate, or stereoisomer thereof, wherein each of ring A and ring B is, independently, one of the following formulas, Formula (IIa), Formula (IIb), Formula (IIc), Formula (IIId), Formula (IIe), Formula (IIIf), Formula (IIg) and values for the remaining variables (e.g., Linker, ring C, R¹, R², R³, R⁴, R⁵, m, n, o) are as described herein.

[Continued on next page]

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*